| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| 250mg |
| ln Vitro |
Cell viability is lowered by aciclovir sodium (3-100 µM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) in a way that is dependent on both dose and time [1]. Aciclovir sodium (10-100 µM; 24-72 hours; Jurkat cells) raises the sub-G1 hypodiploid peak and inhibits DNA synthesis, stopping the cell cycle in the G2/M and S phases. 1]. Aciclovir sodium (10-100 µM; 24-72 hours; Jurkat cells) activates caspase-3 and fragments nuclear DNA to cause apoptosis [1].
|
|---|---|
| ln Vivo |
Aciclovir sodium (20 mg/kg; oral; three times daily; 10 days) prevents skin lesions from forming and separates the formation of antibodies from DTH reactions. [3]
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Jurkat, U937 and K562 Leukemia cell Tested Concentrations: 3, 10, 30 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: demonstrated a dose and time dependent decrease in cell viability. Apoptosis analysis[1] Cell Types: Jurkat Cell Tested Concentrations: 10 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Increased caspase-3 activity and cleavage of internucleosomal DNA. Cell cycle analysis[1] Cell Types: Jurkat cells Tested Concentrations: 10 and 100 µM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Dose-dependent accumulation of cells in S phase after 24 and 48 hrs (hours). After 72 hrs (hours), there was a dose-dependent increase in the sub-G1 hypodiploid peak. |
| Animal Protocol |
Animal/Disease Models: Specific - Pathogen-free balb/c (Bagg ALBino) mouse (7 weeks old) infected with HSV-1 [3]
Doses: 20 mg/kg Route of Administration: po (po (oral gavage)) three times daily; for 10 days Experimental Results: Inhibition of skin The lesions develop and result in a dissociation between the DTH response and antibody production. |
| References |
[1]. Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.
[2]. Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. [3]. Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7. [4]. Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44. |
| Molecular Formula |
C8H10N5NAO3
|
|---|---|
| Molecular Weight |
247.18
|
| CAS # |
69657-51-8
|
| Related CAS # |
Acyclovir;59277-89-3;Acyclovir alaninate;84499-64-9
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C1=NC2=C([N]1COCCO)N=C(N=C2[O-])N.[Na+]
|
| Synonyms |
Aciclovir sodiumAcyclovir sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0456 mL | 20.2282 mL | 40.4563 mL | |
| 5 mM | 0.8091 mL | 4.0456 mL | 8.0913 mL | |
| 10 mM | 0.4046 mL | 2.0228 mL | 4.0456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
